BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI (TEM) to $75 from $65 and keeps a Buy rating on the shares ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade TEMPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- HIMS vs. LLY vs. TEM: Which Healthcare Stock Is Wall Street’s Top Buy Right Now?
- Cathie Wood Bets Over $17M on Crypto and AI Stocks, 7/17/2025
- Cathie Wood’s ARK Investment buys 20.1K shares of Tempus AI today
- Moderately bullish activity in tempus AI Inc Class A with shares up 7.31%
- tempus AI Inc Class A call volume above normal and directionally bullish